📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

AI-based diagnosis for improving classification of bone and soft tissue tumours across the UK

Lead Research Organisation: UNIVERSITY COLLEGE LONDON
Department Name: Medical Physics and Biomedical Eng

Abstract

Delivery of pathology tissue diagnoses, most of which are cancer, in the current format is unsustainable. Advances in genomic medicine and immune-oncology have shown that the classification of tumours into subtypes allows selection of patients for specific treatments but also spares patients unnecessary toxic and expensive therapies. Still, making such diagnoses has become more time-consuming, involving the selection and interpretation of ancillary tests which requires an ever-growing specialist knowledge for each cancer type. Whilst the need for diagnostic expertise is increasing, there is already a shortfall of 25% of pathologists who are able to report results: this is set to decline.

We propose that the use of AI can ensure that the delivery of tissue diagnoses by pathologists is sustainable and supports delivery of personalised treatments. The benefits of AI in pathology are beginning to be seen, e.g. identification of high-grade areas of prostate cancer shows a reduction in errors and pathologists' time. The development of AI for diagnoses is timely as full adoption of digitised histological images, allowing them to be interrogated by both humans and artificial intelligence (AI), is expected in the UK by 2025.

AI is a data-hungry process; it is unrealistic to provide 100,000s images that are required to train a model. Even the most common cancers (e.g. breast) have multiple subtypes; identification of these is required for selection of patients for personalised treatments. To address this challenge, we propose to develop a novel AI strategy using a relatively small sample size (~1000 images per class). Such a model could be adapted to any cancer type. A multiple-instance learning framework will be developed, using transformers for feature extraction and classification. A tool that flags samples that cannot be confidently classified will be applied thereby alerting the pathologist of potentially unseen diseases. The deep learning model will be strengthened by the injection of pathologists' domain knowledge.

Soft tissue and bone tumours
We will develop the AI model on tumours of soft tissue (muscle, fat, blood vessels, etc.) and bone, an area considered to be one of the most challenging diagnostically. These tumours comprise approximately 100 different subtypes, and represent some of the most common cancers in children and young adults.

We will build on our existing deep learning model of 15 different subtypes trained on 2122 images, which predicts the correct diagnosis in 87% of cases. Selection of confirmatory ancillary tests is then prompted by the algorithm and streamlines the diagnostic pathway.

17,000 images that have already been scanned will be added to the library and allow the rapid development and extension of the classification model. The image library will be linked to clinical outcomes and expanded to 35,000 images during the project. Added to this is the commitment of the established Sarcoma Network of at least 20 pathologists from across all countries in the UK, to provide the additional 20,000 images mentioned above.

Additional benefits
The study and infrastructure will serve as the framework for the continued development of the model which can rapidly be expanded prospectively with the introduction of digital pathology in the NHS and globally. The model can be developed over time in response to new advances.

The image library will be available for training future pathologists, research, validation of other AI algorithms, and contribute to the Sarcoma Genomics England Clinical Interpretation Partnership (GeCIP) offering a valuable resource for future multi-modal multi-omic research.

Working closely with Sarcoma charities, and partners, we will involve and engage patients, their families, and the public, to build trust in the use of AI in health care.

Development of AI models for digitised pathology images can avert the crisis facing this medical specialty.

Publications

10 25 50
 
Description We have strongly demonstrated that an AI algorithm can outperform a pathologist alone on the diagnosis of sarcomas, and we have demonstrated that the combination of AI and pathologists provide the best overall results. This effort will severely streamline the pathway to sarcoma diagnosis. Besides, some of the algorithms developed within the scope of this grant were used later on to colorectal cancer, where we demonstrated significant improvement in survival.
Exploitation Route We are looking at commercialisation efforts to bring this AI algorithm to the NHS, as we believe its impact will be significant, by helping reducing healthcare cost in unneccesary tests, and accelerating the pathway to diagnostic, improving overall survival.
Sectors Healthcare

URL http://octopath.ai
 
Description We are currently in discussion to bring a commercial aspect to the research done via this award, in-line with the grants requirement. We are also in discussion with UCL Business to protect the IP generated.
First Year Of Impact 2024
Sector Healthcare
Impact Types Economic

 
Description Gap Fund
Amount £237,016 (GBP)
Funding ID APP81058 
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 01/2026 
End 12/2026
 
Description Travel Grant: Outcome Prediction for Rectal Cancer Neoadjuvant Chemoradiotherapy using Digital Pathology and Artificial Intelligence on Clinical Trial Cohorts in UK and China
Amount £44,843 (GBP)
Funding ID APP53858 
Organisation United Kingdom Research and Innovation 
Sector Public
Country United Kingdom
Start 01/2026 
End 03/2026
 
Description UCL Therapeutic Acceleration Support - Octopath
Amount £80,000 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 08/2025 
End 09/2026
 
Description UCL's HEIF Early stage commercialisation / Proof of concept applicatio
Amount £57,675 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 01/2026 
End 12/2026
 
Description iCURE Explore Funding
Amount £36,166 (GBP)
Funding ID EXSEP25-59 / 524129150 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 08/2025 
End 12/2025
 
Title Web Application to deploy easily our AI model 
Description We launched a web application that enables direct use of our AI model for digital pathology without any knowledge about progamming. This platform is aimed at making it easy for clinicians and researchers to access and work with our AI tools for analyzing pathology slides. In line with our commitment to open science, we've also open-sourced the AI model and published detailed documentation on its development and performance. This approach is designed to encourage collaboration and facilitate the model's adoption and improvement by the global scientific and medical communities. We hope to drive engagement of the clinican and that the model can be used in a clinical trial scenario to provide proof for certification. 
Type Of Material Improvements to research infrastructure 
Year Produced 2023 
Provided To Others? Yes  
Impact We are already collaborating with engaged clinician at Sheffield Hospital, the Royal National Orthopaedic Hospital, and at the School of Medicine, Medical Sciences & Nutrition from the University of Aberdeen that are testing our models for sarcoma classification, lymphocites detection and mitoses detection. 
URL http://www.sarcoma-ai.com
 
Title Immunocto: a massive immune cell database auto-generated for histopathology 
Description As a first step towards building models that can recognise immune cells in WSIs, we introduce Immunocto, a high-resolution (40 x magnification) massive database of 2,282,818 immune cells distributed across 4 immune cell subtypes (CD4 T-cells, CD8+ T-cells, B-cells, and macrophages). To our knowledge, Immunocto is the largest available dataset of immune cells extracted from H\&E WSIs by an order of magnitude. All models trained with this database can be tried at www.octopath.ai 
Type Of Material Database/Collection of data 
Year Produced 2024 
Provided To Others? Yes  
Impact This database has stirred the establishment of Octopath, our new startup that aims at delivering services for the UK in AI digital histopathology. 
URL https://zenodo.org/doi/10.5281/zenodo.11073372
 
Title OMG-Octo: Uniformised large scale database of mitotic cells 
Description In this study, we established a large uniform database of pan-cancer mitotic figures (MFs) by deploying the Segment Anything Model (SAM), a foundation object detection model, in five open-source datasets (ICPR, TUPAC, CCMCT, CMC, MIDOG++) using a single nuclei mask format. Manual revision of the masks was performed to maximise database quality. Then, we contributed an in-house dataset of human soft tissue tumours (STT) MFs (N=8,400) (Soft-Tissue Mitotic Figures, STMF). Although STT represents a rare tumour group, they comprise over 100 subtypes exhibiting a wide variety of histological appearances and mimic other tumours including common cancers such as melanoma, carcinoma and lymphoma. STT harbours a variable number of MFs and aids in reaching a diagnosis and predicting disease behaviour.  The STMF was initiated by staining WSIs with an anti-phosphorylated histone H3 (pHH3) antibody to target MFs which was expanded and improved by AI-assisted annotations made by pathologists. 
Type Of Material Database/Collection of data 
Year Produced 2024 
Provided To Others? Yes  
Impact the largest database of its kind for mitotic figure detection training of AI model. 
URL https://zenodo.org/doi/10.5281/zenodo.11521640
 
Title OMG-Octo: Uniformised large scale database of mitotic figures in Haematoxylin and Eosin-Stained Slides 
Description In this study, we established a large uniform database of pan-cancer mitotic figures (MFs) by deploying the Segment Anything Model (SAM), a foundation object detection model, in five open-source datasets (ICPR, TUPAC, CCMCT, CMC, MIDOG++) using a single nuclei mask format. Manual revision of the masks was performed to maximise database quality. Then, we contributed an in-house dataset of human soft tissue tumours (STT) MFs (N=8,400) (Soft-Tissue Mitotic Figures, STMF). Although STT represents a rare tumour group, they comprise over 100 subtypes exhibiting a wide variety of histological appearances and mimic other tumours including common cancers such as melanoma, carcinoma and lymphoma. STT harbours a variable number of MFs and aids in reaching a diagnosis and predicting disease behaviour.  The STMF was initiated by staining WSIs with an anti-phosphorylated histone H3 (pHH3) antibody to target MFs which was expanded and improved by AI-assisted annotations made by pathologists. 
Type Of Material Database/Collection of data 
Year Produced 2024 
Provided To Others? Yes  
Impact We have had several business and companies contacting us to get access to the dataset and refine it for further cases, as well as research groups. This database and the Immunocto one really spearheaded our recognition in the field of AI digital pathology. 
URL https://zenodo.org/doi/10.5281/zenodo.11521639
 
Title OctoPath: Large Scale Pathology Single-Cell Database from Immuno-Fluorescence cells 
Description Through the course of the UKRI AI for Health Award, we generated multi-millions single-cell labels for AI training of various cells (mitotic cells, epithelial, lymphocytes CD4/CD8, stromal, muscular, endothelial, macrophages). This database of single cells contains the H&E representation, the mask around the nuclei, as well as the label for each cell. It will be of great usage for any future AI algorithms that wants to train on these datasets and produce new AI algorithm. The database is currently compiled and will soon be published. 
Type Of Material Database/Collection of data 
Year Produced 2024 
Provided To Others? Yes  
Impact Our current publication submitted to Nature: Machine Learning come directly from the generation of this database. As it is yet to be made fully public (last validation), no external impacts have yet been recorded. This section will be filled 
 
Title Sarcoma Histopathology Database 
Description We are accumulating a database of histopathology slides from sarcoma. As of this submission, we have accumulated 7200 slides out of 39 diagnosis of sarcoma, by far the largest database up to date. 
Type Of Material Database/Collection of data 
Year Produced 2025 
Provided To Others? No  
Impact We are currently preparing a manuscript that will detail our new AI algorithm built on this database. This AI algorithm can predict the sarcoma subtype within 39 diagnosis with a top 1 accuracy of roughly 85%, and a top 3 accuracy of above 95%. 
 
Title UK-Based Sarcoma WSI Database 
Description Before 2023: Database of 10k scanned sarcoma whole-slide images, of 22 different diagnosis. This database is not yet public as we are waiting for our own publications to come out, as well as for ethical regulatory approval. Since 2023 with the award of the UKRI AI for Health, we have increased our current number of diagnosis to 29 and currently are collecting 35,000 WSI to train our AI model. 
Type Of Material Database/Collection of data 
Year Produced 2023 
Provided To Others? No  
Impact The large scale database has allowed us to significantly improves the results of our AI algorithms and to produce state-of-the-art results that are incorporated into our latest model. This model will be tested against pathologist and, pending positive results, incorporated in clinical practice through industrial partners. 
 
Title METHOD FOR TRAINING MODELS TO PREDICT LABELS FOR A DIGITAL PATHOLOGY IMAGE 
Description In a first approach of the present techniques, there is provided a computer- implemented method, for generating a training dataset for training a tissue detection model to identify tissue types in a digital image of a tissue section. The method comprises obtaining a first dataset comprising a plurality of paired input digital images and transcriptomic maps and for each paired input digital image and transcriptomic map: segmenting each input digital image into a plurality of tiles; predicting, using a backbone model of the tissue detection model, a morphological signature for each tile of the input digital image, wherein each morphological signature is an embedding of cellular features within the tile; obtaining, from the paired transcriptomic map, a genetic signature for each tile of the input digital image, wherein each genetic signature identifies one or more genetic sequences within the tile; inputting, to a denoising module, the genetic signature and the morphological signature for each tile to generate for each tile a representative genetic vector representing genetic features and a representative morphological vector representing morphological features; generating, using the generated representative vectors, a tissue signature for each tile within the digital image; and obtaining, using the generated tissue signature for each tile, a ground-truth tissue label for each tile. The method further comprises outputting a training dataset comprising a plurality of paired input digital images and labelled digital images, wherein each labelled digital image comprises a tissue label for each tile. At the output stage, there is no need to output the transcriptomic data because the training dataset is sufficient to train the tissue detection model to predict tissue labels without the need for any transcriptomic data, i.e. from an input image only. 
IP Reference  
Protection Patent / Patent application
Year Protection Granted 2026
Licensed No